Jeffrey del Carmen - 29 Mar 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Issuer symbol
CPRX
Transactions as of
29 Mar 2023
Net transactions value
-$540,746
Form type
4
Filing time
30 Mar 2023, 17:01:14 UTC
Previous filing
17 Feb 2023
Next filing
29 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $47,002 +20,983 +278% $2.24* 28,524 29 Mar 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $350,416 -20,983 -74% $16.70 7,541 29 Mar 2023 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $80,062 +19,017 +252% $4.21 26,558 29 Mar 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $317,394 -19,017 -72% $16.69 7,541 29 Mar 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -20,983 -2.9% $0.000000 690,334 29 Mar 2023 Common Stock 20,983 $2.24 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -19,017 -2.8% $0.000000 671,317 29 Mar 2023 Common Stock 19,017 $4.21 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company. Mr. Del Carmen remains an officer of the Company.
F2 Shares were sold in various lots from $16.65 to $16.735 per share. The price listed represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $16.645 to $16.74 per share. The price listed represents a weighted average price for the shares sold.
F4 Options vested in three annual tranches beginning on December 19, 2019.
F5 Options vested in three annual tranches beginning on January 6, 2021.